

Early outcomes of intravitreal aflibercept 8mg in eyes previously treated with aflibercept 2mg for neovascular age-related macular degeneration with AI-based biomarker quantification

Nicolò Bartolomeo, MD^{1*}, Konstantinos Kitsos Kalyvianakis, MD^{1*}, Yannic Pannatier Schuetz, PhD¹, Anna Chiara Nascimbeni, PhD¹, Daniela Gallo Castro, PhD¹, Baptiste Crozat, MSc¹, Mamadou Pathé Barry, PhD¹, Aude Ambresin, MD¹

Affiliations

¹Swiss Visio Retina Research Center, Lausanne, Switzerland


* These authors share the first authorship

Corresponding author

Aude Ambresin, Swiss Visio Retina Research Center, Lausanne, Switzerland

(aambresinsvrrc@swissvisio.net)

Supplementary figure 1- Qualitative analysis of fluid dynamics. Proportion of patients with fluids at baseline and month 6.



IRF intraretinal fluid, *SRF* subretinal fluid, *RPE* retinal pigment epithelium